SCIENT Public Relations

A full-service communications consulting firm serving innovative names in biotech.

[SCIENT Public Relations @scientpr]

Congrats to the @arenabioworks team on welcoming Dr. @HarveyJBerger as Chairman/EO with Co-founder/CSO Dr. @schreiberstuart. It’s been a privilege to support their work combining AI, human biology, and leadership to advance the future of drug discovery.

[Arena BioWorks @arenabioworks]

Arena welcomes @HarveyJBerger as Chairman & CEO, joining Founder & CSO @schreiberstuart to advance our mission. By incorporating causal mechanisms of human disease, we are building a new model for discovering and developing breakthrough medicines. https://t.co/CPYWujXvxI

[SCIENT Public Relations @scientpr]

Congratulations to our #client @theMMRF on publishing the largest single sequencing study of multiple myeloma patients!

We're proud to support a team moving biotech forward and developing better treatments for patients. #biotechpr

[Multiple Myeloma RF @theMMRF]

Today, we announced a new paper on our CoMMpass℠ study with our partners, @WinshipAtEmory & @TGenResearch, which defines distinct subtypes and identifies high-risk genetic markers of #myeloma. Read the announcement here: https://t.co/uLhSAd4IFB

[SCIENT Public Relations @scientpr]

#Client news: Congrats to the team at @jnanatx on recently entering into an agreement to be acquired by Otsuka Pharmaceutical Co., Ltd.

We are proud to support Jnana and excited about this opportunity for Jnana to continue advancing its innovative therapies. #biotechpr

[Jnana Therapeutics @jnanatx]

Jnana announced today that it has entered into an agreement to be acquired by Otsuka Pharmaceutical.
https://t.co/IMXvbxYwaE #biotech #news

[SCIENT Public Relations @scientpr]

#Client news: Congrats to the @Abiologics_Inc team on their launch!

Abiologics was created to reimagine biologics by developing a new class of supranatural and programmable medicines called Synteins™. We are proud to work alongside industry innovators. #biotechpr

[SCIENT Public Relations @scientpr]

Coming in at no. 8 on the @CNBCDisruptors list is @ElevateBio! #client

Their CEO, David Hallal, joined CNBC to speak about how they are trying to power the future of cell & gene therapy development for the entire industry. Watch the clip: https://t.co/CcpvaXAPXW #Disruptor50

[CNBC's Fast Money @CNBCFastMoney]

The disruptive potential for gene and cell therapies is taking center stage in the biotech business

@ElevateBio CEO & Chairman David Hallal talks his company's mission, the road ahead, and the potential impact these therapies could have on patients:

[SCIENT Public Relations @scientpr]

Congrats to our clients, @elevatebio and @generate_biomed, for being named to the @CNBCDisruptors list for their groundbreaking advancements that are reshaping healthcare and driving meaningful change.

Find the #Disruptor50 list: https://t.co/wzeAkg1VWc #biotechpr

[SCIENT Public Relations @scientpr]

March Madness is in full swing & office smack talk is high, but we are sharing laughs around the madness, #FierceMadness that is!

Check out @FierceBiotech's Best Biotech Name Tournament to vote for your favorites. https://t.co/GgDAgaVEIp #BiotechBracket

[SCIENT Public Relations @scientpr]

Congrats @CAMP4 for dosing the first participant in Phase 1 clinical study of CMP-CPS-001! Thrilled to support as they use regulatory RNA to target rare diseases like urea cycle disorders. Exciting to see RNA therapeutics reshape medicine! #biotech #innovation #client

[CAMP4 Therapeutics @camp4tx]

We’re pleased to announce that the first participant has been dosed in the Phase 1 #clinicaltrial of CMP-CPS-001, our first-in-class therapeutic for the potential treatment of #ureacycledisorders (UCDs).

📢 Learn more: https://t.co/H0pVOD5pqL

[SCIENT Public Relations @scientpr]

In today's digital world, we don't often talk about an article being "above the fold" but we're excited to see that our #client @ElevateBio recently scored choice above the fold real estate in the @BostonGlobe Media.

Read more: https://t.co/QKyhGXhney #biotechpr #communications

[SCIENT Public Relations @scientpr]

Highlights of the last full day (Day 3) of the @jpmorgan Healthcare Conference take a different approach - less on investment news & more on the industry's future - don't miss it!

To receive our FULL recap on Friday, contact us. https://t.co/60LqWEwo2d #biotechPR #JPM24 #JPM2024

[SCIENT Public Relations @scientpr]

Catch our Day 2 highlights from the @jpmorgan Healthcare Conference that includes a little friendly #AI banter. 🤨 ⚽

Be the first to receive our Day 3 highlights and let us know that you want to receive our newsletter. https://t.co/nkSZ0jFcM7 #JPM24 #biotechPR

[SCIENT Public Relations @scientpr]

Highlights from Day 1 of the @jpmorgan Healthcare Conference include IPOs, ADCs, VCs, & deals.

Explore our key takeaways from day one of the most influential healthcare investor conference, #JPM24.

Be among the first to receive Day 2 highlights - subscribe! #biotechPR #JPM2024

[SCIENT Public Relations @scientpr]

@KynexisTx has officially launched & is embarking on a transformative journey to redefine the treatment landscape for cognitive impairment associated with schizophrenia (CIAS). Congratulations to the team, & we look forward to supporting their advancements. #client #biotechpr

[Kynexis @KynexisTx]

We’re excited to introduce you to Kynexis!

Led by our CEO, Kees Been, we’re advancing the first precision medicine for the potential treatment of cognitive impairment associated with #schizophrenia (CIAS).

Read to learn more: https://t.co/QlBIFQ6g22 #biotechnology #innovation

[SCIENT Public Relations @scientpr]

Exciting news for @Apnimed!

They’ve formed a joint venture with @SHIONOGI_JP to tackle challenges of obstructive #sleepapnea & other #sleepdisorders. We’re proud to work alongside our #client as they move #biotech forward. https://t.co/KlKwm1wNCi #biotechpr

[SCIENT Public Relations @scientpr]

#FierceBiotechSummit continues! @VergeGenomics CMO, Diego Cadavid, joined a panel on a massively important topic: How AI is and will revolutionize drug discovery and development. #client

[SCIENT Public Relations @scientpr]

It was wonderful celebrating @Apnimed’s inclusion in the #Fierce15 last evening.

Apnimed is pursuing a simple but profound challenge: transforming the treatment of obstructive sleep apnea with the first oral therapy for the condition. #FierceBiotechSummit #client

[SCIENT Public Relations @scientpr]

Our Head of Media & Thought Leadership, Adam Silverstein, will join hundreds of #biotechnology professionals in Boston for two major conferences, #FierceBiotechSummit and #STATSummit.

Watch this space for insights and reflections, and follow him at @a_silverstein.

[SCIENT Public Relations @scientpr]

Boston's vibrant atmosphere was ideal for our brainstorming sessions, where we combined great ideas with strategic planning and plenty of laughter. We're moving biotech forward.

Thank you to @citizenM for hosting us! #societyM #biotechPR

[SCIENT Public Relations @scientpr]

We’re thrilled to share that #client @Apnimed announced their first patient dosed in the Phase 3 LunAIRo #clinicaltrial of AD109, a significant milestone on their journey to make a difference in the lives of people living with obstructive #sleepapnea. #biotechpr #biotechnology

[Apnimed @apnimed]

#BreakingNews: Today, we announced the 1st patient dosed in the Ph 3 LunAIRo #clinicaltrial designed to examine the efficacy & safety of AD109 vs. placebo in a broad range of people w/ #OSA. Details: https://t.co/aWQKC2jNQj #obstructivesleepapnea #sleepdisorders

[SCIENT Public Relations @scientpr]

Exciting #client news! @VergeGenomics announced their multi-target #collaboration with @AlexionPharmaUS. This partnership underscores the power and scalability of their all-in-human CONVERGE™ platform for tech-enabled #drugdiscovery. #biotech #AI #drugdevelopment

[Verge Labs @Verge_Labs]

We're excited to announce Verge's multi-target collaboration with @AlexionPharma to identify novel drug targets for rare neurodegenerative & neuromuscular diseases. Read about our second collaboration with a leading global pharmaceutical company: https://t.co/EFIghtFvHI #AI